Company news
Firefly Neuroscience, Inc. (NASDAQ:AIFF) news
Firefly Neuroscience, Inc. news releases on 6ix. Latest, Sep 25, 2026: Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared…
Press releases & updates
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
September 25, 2026
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
August 5, 2026
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
July 27, 2026
Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
June 1, 2026
With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
April 13, 2026
Firefly Confirms Public-Private Partnership with the Department of War
March 26, 2026
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
March 12, 2026
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
March 4, 2026
Firefly Neuroscience Reports Third Quarter 2025 Financial Results
November 12, 2025
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
September 5, 2025
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
August 26, 2025
Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025
July 28, 2025
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
July 14, 2025
Stran & Company Appoints Veteran Financial Executive Brian M. Posner to its Board of Directors
July 10, 2025
Firefly Neuroscience to be Added to the Russell Microcap® Index
June 23, 2025
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
June 20, 2025
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
May 5, 2025
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
May 5, 2025
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
February 21, 2025
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
January 23, 2025
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
January 13, 2025
Firefly Neuroscience Closes on Financing of up to $12.4 Million
December 30, 2024
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
December 3, 2024
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
November 13, 2024
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 24, 2024
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
October 14, 2024
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
September 19, 2024
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
September 9, 2024
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
September 4, 2024
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
August 20, 2024
Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer
June 19, 2024
Firefly Neuroscience, an AI-Driven Brain Health Company, Names Brian S. Posner to its Board of Directors, Upon Closing of Its Merger Transaction with WaveDancer
May 28, 2024
Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, David Johnson as Executive Chairman, Upon Closing of Its Merger Transaction with WaveDancer
May 13, 2024
FireFly Neuroscience Announces Healthcare Science and AI Industry Leader David DeCaprio to Join Board of Directors
April 16, 2024
Information Analysis Appoints Tim Hannon Interim Chief Financial Officer
October 3, 2021